• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Wockhardt receives USFDA approval for generic version of Augmentin suspension

      Posted AtNews.alibaba.com

      Wockhardt has received USFDA approval for marketing an oral suspension of a combination of amoxycillin and clavulanate potassium. Wockhardt's Chicago-based subsidiary Morton Grove Pharmaceuticals received approval from the USFDA for marketing the suspension containing 250 mg/5 ml of amoxycillin and 62.5 mg/5 ml of clavulanate potassium, which is used for treating several common infections, especially in children. The product is sold in the US by Glaxo SmithKline under the brand name Augmentin 250.

      "Wockhardt is the first company to receive an ANDA approval for this strength of Augmentin. Pediatric products are a major focus area for Morton Grove and this exclusive generic will be one of the several other unique pediatric products in our portfolio," said Habil Khorakiwala, chairman, Wockhardt.

      Wockhardt intends to launch this product in the US sometime in Q3 2009. According to IMS, the market for the 250/62.5 combination of Augmentin in the US is about $ 32 million. The product was developed as a part of a series of collaborative projects along with Cipla Ltd, another pharmaceutical major from India. It will be exclusively manufactured and supplied for Wockhardt by Cipla from its FDA-approved facility in Goa.

      January 09, 2009


       

      Share this Article!

    Back to top^